CHRO logo

Channel Therapeutics (CHRO)

Profile

Full Name

Channel Therapeutics Corporation

Ticker Symbol

CHRO

Exchange

NYSE American

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

February 16, 2024

Indexes

Not included

Website

http://www.chromocell.com

Employees

4

Key Details

Price

$1.30(-3.70%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$0.00(0.00% YoY)

Annual EPS

-

PE ratio

-

Next earnings date

N/A

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$1.30
CHRO price is $1.30

30-Day Relative Volume

0.49
CHRO 30-day relative volume is 0.49

Price Performance

Price Today change

-3.7%
CHRO price is down -3.7% today

Price YTD change

+102.81%
CHRO price is up +102.81% since January 1st

Price 1-year change

-33.33%
CHRO price is down -33.33% year-on-year

Price 3-year change

-
CHRO price 3-year change is unknown

Price Range

Price All-time high

$6.00
CHRO price is currently -78.33% below its historical high of $6.00

Price 3-year low

$0.45
CHRO price is currently +188.89% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$7.50M
CHRO market capitalization is $7.50 million

Market cap 3-year change

-
CHRO market capitalization 3-year change is unknown

Market cap All-time high

$27.68M
CHRO market capitalization is currently -72.92% below its historical high of $27.68 million

Market cap sector rank

16.61%
CHRO market capitalization is higher than 16.61% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

0%
CHRO {parameterFullLabel} has remained unchanged year-on-year

Shares Outstanding 3-Year Change

-
CHRO shares outstanding 3-year change is unknown

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

1.09
CHRO beta is 1.09

200-day SMA

$1.11
CHRO price is currently +16.70% above its 200-day simple moving average

50-day SMA

$1.65
CHRO price is currently -21.09% below its 50-day simple moving average

RSI

40.43
CHRO 14-day relative strength index is 40.43

Volume

0.49
CHRO 30-day relative volume is 0.49

ATR

$0.14
CHRO average true range is $0.14

10-day Historical Volatility

69.84%
CHRO 10-day historical volatility is 69.84%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$0.00
CHRO annual revenue is $0.00

Revenue Analysts estimate

-
CHRO annual revenue consensus analysts' forecast is unknown

Revenue 1-year change

0%
CHRO {parameterFullLabel} has remained unchanged year-on-year

Revenue Sector rank

1.23%
CHRO annual revenue is higher than 1.23% of companies in Healthcare sector

EPS

EPS

-
CHRO annual earnings per share value is unknown

EPS Analysts estimate

-$1.10
CHRO annual earnings per share is currently equal to the consensus analysts' forecast

EPS 1-year change

-
CHRO annual earnings per share 1-year change is unknown

EPS Sector rank

-
CHRO annual earnings per share is unknown

Profit

Gross profit

-
CHRO annual gross profit value is unknown

Gross margin

-
CHRO annual gross profit margin value is unknown

Operating profit

-$7.57M
CHRO annual operating income is -$7.57 million

Operating margin

-
CHRO annual operating profit margin value is unknown

Net income

-$7.96M
CHRO annual net profit is -$7.96 million

Net margin

-
CHRO annual net profit margin value is unknown

Expenses

Total expenses

$7.57M
CHRO annual total expenses is $7.57 million

Operating expenses

$7.57M
CHRO annual total operating expenses is $7.57 million

Cost of goods sold

-
CHRO annual cost of goods sold value is unknown

Selling, general & administrative expenses

$6.39M
CHRO annual SGA is $6.39 million

Depreciation and amortization

-
CHRO annual depreciation & amortization value is unknown

Interest expense

$786.39K
CHRO annual interest expense is $786.39 thousand

Income tax

$0.00
CHRO annual income tax is $0.00

EBIT & EBITDA

EBIT

-$7.17M
CHRO annual earnings before interest & taxes is -$7.17 million

EBITDA

-$7.53M
CHRO annual EBITDA is -$7.53 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$1.37M
CHRO annual total assets is $1.37 million

Non current assets

$0.00
CHRO annual long term assets is $0.00

Current assets

$1.37M
CHRO annual total current assets is $1.37 million

Cash and cash equivalents

$513.44K
CHRO annual cash & cash equivalents is $513.44 thousand

Accounts receivable

-
CHRO annual accounts receivable value is unknown

Inventory

-
CHRO annual inventory value is unknown

Liabilities

Total liabilities

$4.08M
CHRO annual total liabilities is $4.08 million

Long term liabilities

$0.00
CHRO annual total long term liabilities is $0.00

Current liabilities

$4.08M
CHRO annual total current liabilities is $4.08 million

Accounts payable

$1.90M
CHRO annual accounts payable is $1.90 million

Debt

Total debt

$2.19M
CHRO annual total debt is $2.19 million

Total debt 1-year change

+72.31%
CHRO annual total debt is up +72.31% year-on-year

Long term debt

-
CHRO annual long term debt value is unknown

Short term debt

$2.19M
CHRO annual short term debt is $2.19 million

Equity & Capital

Shareholders equity

-$2.71M
CHRO annual stockholders equity is -$2.71 million

Book value

-$2.71M
CHRO annual book value is -$2.71 million

Retained earnings

-$21.47M
CHRO annual retained earnings is -$21.47 million

Working capital

-$2.71M
CHRO annual working capital is -$2.71 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$5.79M
CHRO annual cash flow from operations is -$5.79 million

Cash from operations 1-year change

-490.45%
CHRO annual cash flow from operations is down -490.45% year-on-year

Cash from investing

-
CHRO annual cash flow from investing activities value is unknown

Cash from investing 1-year change

-
CHRO annual cash flow from investing activities 1-year change is unknown

Cash from financing

$6.21M
CHRO annual cash flow from financing activities is $6.21 million

Cash from financing 1-year change

+507.38%
CHRO annual cash flow from financing activities is up +507.38% year-on-year

CAPEX

CAPEX

-
CHRO annual capital expenditures value is unknown

CAPEX 1-year change

-
CHRO annual capital expenditures 1-year change is unknown

Free Cash Flow

Free cash flow

-$5.79M
CHRO annual free cash flow is -$5.79 million

Free cash flow 1-year change

-490.45%
CHRO annual free cash flow is down -490.45% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

-
CHRO annual gross profit margin value is unknown

Operating margin

-
CHRO annual operating profit margin value is unknown

Net margin

-
CHRO annual net profit margin value is unknown

ROA & ROE

ROA

-581.05%
CHRO annual return on assets is -581.05%

ROE

293.12%
CHRO annual return on equity is 293.12%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
CHRO price to earnings ratio value is unknown

PE ratio Sector rank

-
CHRO price to earnings ratio is unknown

PB Ratio

PB ratio

-2.76
CHRO price to book ratio is -2.76

PB ratio Sector rank

5.51%
CHRO price to book ratio is higher than 5.51% of companies in Healthcare sector

PS Ratio

PS ratio

-
CHRO price to sales ratio value is unknown

PS ratio Sector rank

-
CHRO price to sales ratio is unknown

Enterprise value

Enterprise value

$9.17M
CHRO enterprise value is $9.17 million

Enterprise value Sector rank

23.72%
CHRO enterprise value is higher than 23.72% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-1.22
CHRO EV/EBITDA is -1.22

EV/EBITDA Sector rank

40.09%
CHRO EV/EBITDA is higher than 40.09% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

0.34
CHRO annual current ratio is 0.34

Quick ratio

-
CHRO annual quick ratio value is unknown

Leverage

Debt to equity

-0.81
CHRO annual debt to equity ratio is -0.81

Interest coverage ratio

-9.12
CHRO annual interest coverage ratio is -9.12

Risk & Stability

Piotroski F-Score

-
CHRO piotroski f-score value is unknown

Altman Z-Score

-40.52
CHRO altman z-score is -40.52

Analyst ratings

Recent major analysts updates

Jun 18, 24 Alliance Global Partners
Buy

Institutional Ownership

Similar stocks

Scienture Holdings (SCNX)
CANF logo
Can-Fite BioPharma (CANF)
COSM logo
Cosmos Health (COSM)
MYNZ logo
Mainz Biomed BV (MYNZ)
ADXN logo
Addex Therapeutics Ltd (ADXN)
Silexion Therapeutics LTD (SLXN)
OSA logo
ProSomnus (OSA)
INDP logo
Indaptus Therapeutics (INDP)
PMCB logo
PharmaCyte Biotech (PMCB)
  • What is the ticker symbol for Channel Therapeutics?
  • Does Channel Therapeutics pay dividends?
  • What sector is Channel Therapeutics in?
  • What industry is Channel Therapeutics in?
  • What country is Channel Therapeutics based in?
  • When did Channel Therapeutics go public?
  • Is Channel Therapeutics in the S&P 500?
  • Is Channel Therapeutics in the NASDAQ 100?
  • Is Channel Therapeutics in the Dow Jones?
  • When does Channel Therapeutics report earnings?
  • Should I buy Channel Therapeutics stock now?

What is the ticker symbol for Channel Therapeutics?

The ticker symbol for Channel Therapeutics is NYSE American:CHRO

Does Channel Therapeutics pay dividends?

No, Channel Therapeutics does not pay dividends

What sector is Channel Therapeutics in?

Channel Therapeutics is in the Healthcare sector

What industry is Channel Therapeutics in?

Channel Therapeutics is in the Biotechnology industry

What country is Channel Therapeutics based in?

Channel Therapeutics is headquartered in United States

When did Channel Therapeutics go public?

Channel Therapeutics's initial public offering (IPO) was on February 16, 2024

Is Channel Therapeutics in the S&P 500?

No, Channel Therapeutics is not included in the S&P 500 index

Is Channel Therapeutics in the NASDAQ 100?

No, Channel Therapeutics is not included in the NASDAQ 100 index

Is Channel Therapeutics in the Dow Jones?

No, Channel Therapeutics is not included in the Dow Jones index

When does Channel Therapeutics report earnings?

The date for Channel Therapeutics's next earnings report has not been announced yet

Should I buy Channel Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page